VYNE Therapeutics (VYNE) EBIAT (2016 - 2025)
VYNE Therapeutics (VYNE) has disclosed EBIAT for 10 consecutive years, with -$5.8 million as the latest value for Q2 2025.
- For the quarter ending Q2 2025, EBIAT rose 38.75% year-over-year to -$5.8 million, compared with a TTM value of -$38.5 million through Jun 2025, down 35.46%, and an annual FY2025 reading of -$26.5 million, up 33.43% over the prior year.
- EBIAT was -$5.8 million for Q2 2025 at VYNE Therapeutics, up from -$8.6 million in the prior quarter.
- Across five years, EBIAT topped out at $17.6 million in Q4 2021 and bottomed at -$21.6 million in Q2 2022.
- Average EBIAT over 5 years is -$8.9 million, with a median of -$8.9 million recorded in 2022.
- The sharpest move saw EBIAT skyrocketed 175.71% in 2021, then plummeted 220.39% in 2023.
- Year by year, EBIAT stood at $17.6 million in 2021, then tumbled by 144.22% to -$7.8 million in 2022, then grew by 13.26% to -$6.7 million in 2023, then tumbled by 78.46% to -$12.0 million in 2024, then soared by 52.14% to -$5.8 million in 2025.
- Business Quant data shows EBIAT for VYNE at -$5.8 million in Q2 2025, -$8.6 million in Q1 2025, and -$12.0 million in Q4 2024.